Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?

Douglas R. Stewart, Joy D. Cogan, Mordechai R. Kramer, Wallace T. Miller, Leif E. Christiansen, Michael W. Pauciulo, Ludwine M. Messiaen, George S. Tu, William H. Thompson, Reed E. Pyeritz, Jay H. Ryu, William C. Nichols, Makoto Kodama, Barbara O. Meyrick, David J. Ross

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

Background: Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. Methods: We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which is mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Results: Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Conclusions: Our findings suggest that NF1 should be considered as being "associated with PAH"as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.

Original languageEnglish (US)
Pages (from-to)798-808
Number of pages11
JournalChest
Volume132
Issue number3
DOIs
StatePublished - Sep 2007

Keywords

  • Bone morphogenic protein 2
  • Mosaic perfusion pattern of lung attenuation
  • Neurofibromatosis type 1
  • Plexiform arteriopathy
  • Vasculopathy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy?'. Together they form a unique fingerprint.

  • Cite this

    Stewart, D. R., Cogan, J. D., Kramer, M. R., Miller, W. T., Christiansen, L. E., Pauciulo, M. W., Messiaen, L. M., Tu, G. S., Thompson, W. H., Pyeritz, R. E., Ryu, J. H., Nichols, W. C., Kodama, M., Meyrick, B. O., & Ross, D. J. (2007). Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest, 132(3), 798-808. https://doi.org/10.1378/chest.06-3017